Greenwich LifeSciences (GLSI) CEO buys 1,500 company shares

Rhea-AI Filing Summary

Greenwich LifeSciences, Inc. director, CEO and CFO Snehal Patel purchased 1,500 shares of common stock on July 27, 2026 at $13.62 per share in a transaction described as a purchase in open market or private transaction, increasing his direct ownership to 5,609,202 shares. The transaction was not reported as pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 1,500 shares

Net Buy 1 txn

Insider Patel Snehal

Role CEO and CFO

Bought 1,500 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,500	$13.62	$20K

Holdings After Transaction: Common Stock — 5,609,202 shares (Direct)

Key Figures

Shares purchased: 1,500 shares Purchase price: $13.62 per share Post-transaction holdings: 5,609,202 shares +1 more

4 metrics

Shares purchased 1,500 shares Common stock purchase on July 27, 2026

Purchase price $13.62 per share Average price for the 1,500-share common stock transaction

Post-transaction holdings 5,609,202 shares Direct common stock owned by Snehal Patel after the purchase

Net buy shares 1,500 shares Net common stock change across all reported transactions in this filing

Key Terms

ten percent owner, open market or private transaction, Rule 10b5-1 trading plan

3 terms

ten percent owner regulatory

"The reporting person is identified as a <b>ten percent owner</b> of the issuer."

open market or private transaction market

"The purchase code description notes an <b>open market or private transaction</b>."

Rule 10b5-1 trading plan regulatory

"A checkbox indicates whether trades were under a <b>Rule 10b5-1 trading plan</b>."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 06:07 AM Accepted by SEC EDGAR 07/29/2026 - 06:05 AM Learn about SEC filing dates

FAQ

What insider share purchase did GLSI report for Snehal Patel?

Snehal Patel, CEO, CFO and director of Greenwich LifeSciences, bought 1,500 shares of common stock on July 27, 2026 at $13.62 per share. The transaction, described as a purchase in open market or private transaction, raised his direct holdings to 5,609,202 shares.

At what price did GLSI's CEO buy the 1,500 shares of common stock?

The 1,500 Greenwich LifeSciences shares were purchased at an average price of $13.62 per share. This price comes from the reported transaction data for the July 27, 2026 common stock purchase classified as an open market or private transaction.

How many GLSI shares does Snehal Patel hold after this Form 4 transaction?

After the reported purchase, Snehal Patel directly owns 5,609,202 shares of Greenwich LifeSciences common stock. This post-transaction ownership figure reflects his holdings immediately following the July 27, 2026 acquisition of 1,500 additional shares.

Was Snehal Patel's GLSI trade made under a Rule 10b5-1 trading plan?

The filing indicates the transaction was not reported as being made under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is shown as unchecked, meaning the reported purchase was not affirmed as executed pursuant to such a plan.

Is Snehal Patel considered a 10% owner of Greenwich LifeSciences (GLSI)?

Yes. The reporting person, Snehal Patel, is identified as a ten percent owner of Greenwich LifeSciences in addition to serving as its CEO, CFO and director. This status is reflected in the ownership attributes included with the Form 4 data.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Snehal

(Last) (First) (Middle)

C/O GREENWICH LIFESCIENCES, INC.

3992 BLUEBONNET DR., BUILDING 14

(Street)

STAFFORD TEXAS 77477

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Greenwich LifeSciences, Inc. [ GLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		P		1,500	A	$13.62	5,609,202	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Snehal Patel	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)